An enkephalinergic mechanism involved in amygdaloid suppression of affective defence behavior elicited from the midbrain periaqueductal gray in the cat

A series of recent studies in our laboratory have provided evidence that opioid peptides powerfully suppress feline affective defense behavior at the level of the midbrain periaqueductal gray (PAG). In the present study, we tested the hypothesis that the central (CE) nucleus of the amygdala constitu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Brain research 1991-09, Vol.559 (1), p.109-117
Hauptverfasser: Shaikh, Majid B., Lu, Chang-Lin, Siegel, Allan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 117
container_issue 1
container_start_page 109
container_title Brain research
container_volume 559
creator Shaikh, Majid B.
Lu, Chang-Lin
Siegel, Allan
description A series of recent studies in our laboratory have provided evidence that opioid peptides powerfully suppress feline affective defense behavior at the level of the midbrain periaqueductal gray (PAG). In the present study, we tested the hypothesis that the central (CE) nucleus of the amygdala constitutes a significant inhibitory input to the PAG which utilizes enkephalins as its neurotransmitter or neuromodulator. Cannula-electrodes were implanted into the PAG for the elicitation of affective defense behavior as well as for infusion of opioid antagonists. Monopolar stimulating electrodes were also implanted into the central, lateral and medial amygdaloid nuclei from which suppression or facilitation of affective defense behavior could be obtained. Initially, 4 trials of concurrent, subseizure stimulation of the CE or lateral amygdala at very low (100 μA, 60 Hz) currents and PAG resulted in an immediate suppression of this response which displayed a time dependent decline after 30 min. In the next stage of the experiment, naloxone (2.7, 18.9 and 27.5 nM) was microinjected through the cannula-electrode into the PAG affective defense site and the experimental procedures noted above were repeated. Naloxone treatment (at 27.5 and 18.9 nM) blocked the suppressive effects of CE and lateral amygdaloid stimulation in a dose and time dependent manner. Further analysis revealed that this effect is likely mediated via the μ receptor since the suppressive effects of amygdaloid stimulation were blocked by the selective μ antagonist, β-Funaltrexamine (0.05 and 0.2 nM) but not by the selective σ-antagonist, ICI 174,864 (0.7 nM). Moreover, facilitation of affective defense behavior following dual stimulation of the medial amygdala and PAG was not affected by naloxone administration (27.5 nM). The final stage of the study was designed to further test the hypothesis that neurons in the CE contain cell bodies that are both enkephalinergic and project to the dorsal aspect of the PAG associated with the expression of affective defense behavior. This aspect involved the combination of retrograde tracing of amygdaloid neurons into the PAG following microinjections of the retrograde tracer, Fluoro-Gold, and the immunocytochemical analysis of amygdaloid cells that immunoreact positively for Met-enkephalin. The results indicated the presence of many retrogradely labelled and immunocytochemically positive cells within the CE and adjoining regions of the lateral nucleus as well as other
doi_str_mv 10.1016/0006-8993(91)90293-5
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72644728</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0006899391902935</els_id><sourcerecordid>72644728</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-3b5943973d5182d4e439a17bd0246044a9376950e5e7b68174824deb7bf00a83</originalsourceid><addsrcrecordid>eNqFkctu1DAUhi0EKtPCG4DkBUJlEfAtdrypVFXcpEpsurcc-2TGkMTBTiLNk_C6OMyo7GBlW-c7_znyh9ArSt5TQuUHQoisGq35tabvNGGaV_UTtKONYpVkgjxFu0fkObrM-Xt5cq7JBbqgUgqm2A79uh0xjD9gOtg-jJD2weEB3MGOIQ84jGvsV_Dlgu1w3Hvbx-BxXqYpQc4hjjh22HYduDmsgD10MDrALRzsGmLC0AcX5hLQpTjg-QB4CL5NtuRNkIL9uYBf3Gx7vE_2uI3ZGGfnF-hZZ_sML8_nFXr49PHh7kt1_-3z17vb-8oJquaKt7UWXCvua9owL6A8LFWtJ0xIIoTVXEldE6hBtbKhSjRMeGhV2xFiG36F3p5ipxTLLnk2Q8gO-t6OEJdsFJNCKPZ_kJZpnOm6gOIEuhRzTtCZKYXBpqOhxGzezCbFbFKMpuaPN7O1vT7nL-0A_m_TSVSpvznXbXa275IdXciPWE0Io3Jb8-aEQfmzNUAy2YVNiQ-pODI-hn_v8Rsn2bXK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16043295</pqid></control><display><type>article</type><title>An enkephalinergic mechanism involved in amygdaloid suppression of affective defence behavior elicited from the midbrain periaqueductal gray in the cat</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Shaikh, Majid B. ; Lu, Chang-Lin ; Siegel, Allan</creator><creatorcontrib>Shaikh, Majid B. ; Lu, Chang-Lin ; Siegel, Allan</creatorcontrib><description>A series of recent studies in our laboratory have provided evidence that opioid peptides powerfully suppress feline affective defense behavior at the level of the midbrain periaqueductal gray (PAG). In the present study, we tested the hypothesis that the central (CE) nucleus of the amygdala constitutes a significant inhibitory input to the PAG which utilizes enkephalins as its neurotransmitter or neuromodulator. Cannula-electrodes were implanted into the PAG for the elicitation of affective defense behavior as well as for infusion of opioid antagonists. Monopolar stimulating electrodes were also implanted into the central, lateral and medial amygdaloid nuclei from which suppression or facilitation of affective defense behavior could be obtained. Initially, 4 trials of concurrent, subseizure stimulation of the CE or lateral amygdala at very low (100 μA, 60 Hz) currents and PAG resulted in an immediate suppression of this response which displayed a time dependent decline after 30 min. In the next stage of the experiment, naloxone (2.7, 18.9 and 27.5 nM) was microinjected through the cannula-electrode into the PAG affective defense site and the experimental procedures noted above were repeated. Naloxone treatment (at 27.5 and 18.9 nM) blocked the suppressive effects of CE and lateral amygdaloid stimulation in a dose and time dependent manner. Further analysis revealed that this effect is likely mediated via the μ receptor since the suppressive effects of amygdaloid stimulation were blocked by the selective μ antagonist, β-Funaltrexamine (0.05 and 0.2 nM) but not by the selective σ-antagonist, ICI 174,864 (0.7 nM). Moreover, facilitation of affective defense behavior following dual stimulation of the medial amygdala and PAG was not affected by naloxone administration (27.5 nM). The final stage of the study was designed to further test the hypothesis that neurons in the CE contain cell bodies that are both enkephalinergic and project to the dorsal aspect of the PAG associated with the expression of affective defense behavior. This aspect involved the combination of retrograde tracing of amygdaloid neurons into the PAG following microinjections of the retrograde tracer, Fluoro-Gold, and the immunocytochemical analysis of amygdaloid cells that immunoreact positively for Met-enkephalin. The results indicated the presence of many retrogradely labelled and immunocytochemically positive cells within the CE and adjoining regions of the lateral nucleus as well as others that were double labelled. The overall findings support the view that the CE powerfully inhibits affective defense behavior at the level of the PAG and that this phenomenon is mediated via an enkephalinergic mechanism.</description><identifier>ISSN: 0006-8993</identifier><identifier>EISSN: 1872-6240</identifier><identifier>DOI: 10.1016/0006-8993(91)90293-5</identifier><identifier>PMID: 1664272</identifier><identifier>CODEN: BRREAP</identifier><language>eng</language><publisher>London: Elsevier B.V</publisher><subject>Affect - physiology ; Affective defense behavior ; Aggression - physiology ; Amygdala ; Amygdala - physiology ; Anatomical correlates of behavior ; Animals ; Behavioral psychophysiology ; Biological and medical sciences ; Cats ; Electric Stimulation ; Enkephalin, Leucine - analogs &amp; derivatives ; Enkephalin, Leucine - pharmacology ; Enkephalins - physiology ; Female ; Fluorescent Dyes ; Fundamental and applied biological sciences. Psychology ; Homocysteine - analogs &amp; derivatives ; Homocysteine - pharmacology ; ICI 171, 864 ; Immunohistochemistry ; Male ; Midbrain periaqueductal gray ; Naloxone ; Naloxone - pharmacology ; Naltrexone - analogs &amp; derivatives ; Naltrexone - pharmacology ; Narcotic Antagonists - pharmacology ; Opioid subtype ; Periaqueductal Gray - anatomy &amp; histology ; Periaqueductal Gray - physiology ; Psychology. Psychoanalysis. Psychiatry ; Psychology. Psychophysiology ; Receptors, Opioid - physiology ; Receptors, Opioid, delta ; Receptors, Opioid, mu ; Stereotyped Behavior - physiology ; Stilbamidines ; β-Funaltrexamine</subject><ispartof>Brain research, 1991-09, Vol.559 (1), p.109-117</ispartof><rights>1991 Elsevier Science Publishers B.V. All rights reserved</rights><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-3b5943973d5182d4e439a17bd0246044a9376950e5e7b68174824deb7bf00a83</citedby><cites>FETCH-LOGICAL-c417t-3b5943973d5182d4e439a17bd0246044a9376950e5e7b68174824deb7bf00a83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/0006899391902935$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=5002168$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1664272$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shaikh, Majid B.</creatorcontrib><creatorcontrib>Lu, Chang-Lin</creatorcontrib><creatorcontrib>Siegel, Allan</creatorcontrib><title>An enkephalinergic mechanism involved in amygdaloid suppression of affective defence behavior elicited from the midbrain periaqueductal gray in the cat</title><title>Brain research</title><addtitle>Brain Res</addtitle><description>A series of recent studies in our laboratory have provided evidence that opioid peptides powerfully suppress feline affective defense behavior at the level of the midbrain periaqueductal gray (PAG). In the present study, we tested the hypothesis that the central (CE) nucleus of the amygdala constitutes a significant inhibitory input to the PAG which utilizes enkephalins as its neurotransmitter or neuromodulator. Cannula-electrodes were implanted into the PAG for the elicitation of affective defense behavior as well as for infusion of opioid antagonists. Monopolar stimulating electrodes were also implanted into the central, lateral and medial amygdaloid nuclei from which suppression or facilitation of affective defense behavior could be obtained. Initially, 4 trials of concurrent, subseizure stimulation of the CE or lateral amygdala at very low (100 μA, 60 Hz) currents and PAG resulted in an immediate suppression of this response which displayed a time dependent decline after 30 min. In the next stage of the experiment, naloxone (2.7, 18.9 and 27.5 nM) was microinjected through the cannula-electrode into the PAG affective defense site and the experimental procedures noted above were repeated. Naloxone treatment (at 27.5 and 18.9 nM) blocked the suppressive effects of CE and lateral amygdaloid stimulation in a dose and time dependent manner. Further analysis revealed that this effect is likely mediated via the μ receptor since the suppressive effects of amygdaloid stimulation were blocked by the selective μ antagonist, β-Funaltrexamine (0.05 and 0.2 nM) but not by the selective σ-antagonist, ICI 174,864 (0.7 nM). Moreover, facilitation of affective defense behavior following dual stimulation of the medial amygdala and PAG was not affected by naloxone administration (27.5 nM). The final stage of the study was designed to further test the hypothesis that neurons in the CE contain cell bodies that are both enkephalinergic and project to the dorsal aspect of the PAG associated with the expression of affective defense behavior. This aspect involved the combination of retrograde tracing of amygdaloid neurons into the PAG following microinjections of the retrograde tracer, Fluoro-Gold, and the immunocytochemical analysis of amygdaloid cells that immunoreact positively for Met-enkephalin. The results indicated the presence of many retrogradely labelled and immunocytochemically positive cells within the CE and adjoining regions of the lateral nucleus as well as others that were double labelled. The overall findings support the view that the CE powerfully inhibits affective defense behavior at the level of the PAG and that this phenomenon is mediated via an enkephalinergic mechanism.</description><subject>Affect - physiology</subject><subject>Affective defense behavior</subject><subject>Aggression - physiology</subject><subject>Amygdala</subject><subject>Amygdala - physiology</subject><subject>Anatomical correlates of behavior</subject><subject>Animals</subject><subject>Behavioral psychophysiology</subject><subject>Biological and medical sciences</subject><subject>Cats</subject><subject>Electric Stimulation</subject><subject>Enkephalin, Leucine - analogs &amp; derivatives</subject><subject>Enkephalin, Leucine - pharmacology</subject><subject>Enkephalins - physiology</subject><subject>Female</subject><subject>Fluorescent Dyes</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Homocysteine - analogs &amp; derivatives</subject><subject>Homocysteine - pharmacology</subject><subject>ICI 171, 864</subject><subject>Immunohistochemistry</subject><subject>Male</subject><subject>Midbrain periaqueductal gray</subject><subject>Naloxone</subject><subject>Naloxone - pharmacology</subject><subject>Naltrexone - analogs &amp; derivatives</subject><subject>Naltrexone - pharmacology</subject><subject>Narcotic Antagonists - pharmacology</subject><subject>Opioid subtype</subject><subject>Periaqueductal Gray - anatomy &amp; histology</subject><subject>Periaqueductal Gray - physiology</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychology. Psychophysiology</subject><subject>Receptors, Opioid - physiology</subject><subject>Receptors, Opioid, delta</subject><subject>Receptors, Opioid, mu</subject><subject>Stereotyped Behavior - physiology</subject><subject>Stilbamidines</subject><subject>β-Funaltrexamine</subject><issn>0006-8993</issn><issn>1872-6240</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkctu1DAUhi0EKtPCG4DkBUJlEfAtdrypVFXcpEpsurcc-2TGkMTBTiLNk_C6OMyo7GBlW-c7_znyh9ArSt5TQuUHQoisGq35tabvNGGaV_UTtKONYpVkgjxFu0fkObrM-Xt5cq7JBbqgUgqm2A79uh0xjD9gOtg-jJD2weEB3MGOIQ84jGvsV_Dlgu1w3Hvbx-BxXqYpQc4hjjh22HYduDmsgD10MDrALRzsGmLC0AcX5hLQpTjg-QB4CL5NtuRNkIL9uYBf3Gx7vE_2uI3ZGGfnF-hZZ_sML8_nFXr49PHh7kt1_-3z17vb-8oJquaKt7UWXCvua9owL6A8LFWtJ0xIIoTVXEldE6hBtbKhSjRMeGhV2xFiG36F3p5ipxTLLnk2Q8gO-t6OEJdsFJNCKPZ_kJZpnOm6gOIEuhRzTtCZKYXBpqOhxGzezCbFbFKMpuaPN7O1vT7nL-0A_m_TSVSpvznXbXa275IdXciPWE0Io3Jb8-aEQfmzNUAy2YVNiQ-pODI-hn_v8Rsn2bXK</recordid><startdate>19910913</startdate><enddate>19910913</enddate><creator>Shaikh, Majid B.</creator><creator>Lu, Chang-Lin</creator><creator>Siegel, Allan</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>19910913</creationdate><title>An enkephalinergic mechanism involved in amygdaloid suppression of affective defence behavior elicited from the midbrain periaqueductal gray in the cat</title><author>Shaikh, Majid B. ; Lu, Chang-Lin ; Siegel, Allan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-3b5943973d5182d4e439a17bd0246044a9376950e5e7b68174824deb7bf00a83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Affect - physiology</topic><topic>Affective defense behavior</topic><topic>Aggression - physiology</topic><topic>Amygdala</topic><topic>Amygdala - physiology</topic><topic>Anatomical correlates of behavior</topic><topic>Animals</topic><topic>Behavioral psychophysiology</topic><topic>Biological and medical sciences</topic><topic>Cats</topic><topic>Electric Stimulation</topic><topic>Enkephalin, Leucine - analogs &amp; derivatives</topic><topic>Enkephalin, Leucine - pharmacology</topic><topic>Enkephalins - physiology</topic><topic>Female</topic><topic>Fluorescent Dyes</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Homocysteine - analogs &amp; derivatives</topic><topic>Homocysteine - pharmacology</topic><topic>ICI 171, 864</topic><topic>Immunohistochemistry</topic><topic>Male</topic><topic>Midbrain periaqueductal gray</topic><topic>Naloxone</topic><topic>Naloxone - pharmacology</topic><topic>Naltrexone - analogs &amp; derivatives</topic><topic>Naltrexone - pharmacology</topic><topic>Narcotic Antagonists - pharmacology</topic><topic>Opioid subtype</topic><topic>Periaqueductal Gray - anatomy &amp; histology</topic><topic>Periaqueductal Gray - physiology</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychology. Psychophysiology</topic><topic>Receptors, Opioid - physiology</topic><topic>Receptors, Opioid, delta</topic><topic>Receptors, Opioid, mu</topic><topic>Stereotyped Behavior - physiology</topic><topic>Stilbamidines</topic><topic>β-Funaltrexamine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shaikh, Majid B.</creatorcontrib><creatorcontrib>Lu, Chang-Lin</creatorcontrib><creatorcontrib>Siegel, Allan</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Brain research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shaikh, Majid B.</au><au>Lu, Chang-Lin</au><au>Siegel, Allan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An enkephalinergic mechanism involved in amygdaloid suppression of affective defence behavior elicited from the midbrain periaqueductal gray in the cat</atitle><jtitle>Brain research</jtitle><addtitle>Brain Res</addtitle><date>1991-09-13</date><risdate>1991</risdate><volume>559</volume><issue>1</issue><spage>109</spage><epage>117</epage><pages>109-117</pages><issn>0006-8993</issn><eissn>1872-6240</eissn><coden>BRREAP</coden><abstract>A series of recent studies in our laboratory have provided evidence that opioid peptides powerfully suppress feline affective defense behavior at the level of the midbrain periaqueductal gray (PAG). In the present study, we tested the hypothesis that the central (CE) nucleus of the amygdala constitutes a significant inhibitory input to the PAG which utilizes enkephalins as its neurotransmitter or neuromodulator. Cannula-electrodes were implanted into the PAG for the elicitation of affective defense behavior as well as for infusion of opioid antagonists. Monopolar stimulating electrodes were also implanted into the central, lateral and medial amygdaloid nuclei from which suppression or facilitation of affective defense behavior could be obtained. Initially, 4 trials of concurrent, subseizure stimulation of the CE or lateral amygdala at very low (100 μA, 60 Hz) currents and PAG resulted in an immediate suppression of this response which displayed a time dependent decline after 30 min. In the next stage of the experiment, naloxone (2.7, 18.9 and 27.5 nM) was microinjected through the cannula-electrode into the PAG affective defense site and the experimental procedures noted above were repeated. Naloxone treatment (at 27.5 and 18.9 nM) blocked the suppressive effects of CE and lateral amygdaloid stimulation in a dose and time dependent manner. Further analysis revealed that this effect is likely mediated via the μ receptor since the suppressive effects of amygdaloid stimulation were blocked by the selective μ antagonist, β-Funaltrexamine (0.05 and 0.2 nM) but not by the selective σ-antagonist, ICI 174,864 (0.7 nM). Moreover, facilitation of affective defense behavior following dual stimulation of the medial amygdala and PAG was not affected by naloxone administration (27.5 nM). The final stage of the study was designed to further test the hypothesis that neurons in the CE contain cell bodies that are both enkephalinergic and project to the dorsal aspect of the PAG associated with the expression of affective defense behavior. This aspect involved the combination of retrograde tracing of amygdaloid neurons into the PAG following microinjections of the retrograde tracer, Fluoro-Gold, and the immunocytochemical analysis of amygdaloid cells that immunoreact positively for Met-enkephalin. The results indicated the presence of many retrogradely labelled and immunocytochemically positive cells within the CE and adjoining regions of the lateral nucleus as well as others that were double labelled. The overall findings support the view that the CE powerfully inhibits affective defense behavior at the level of the PAG and that this phenomenon is mediated via an enkephalinergic mechanism.</abstract><cop>London</cop><cop>Amsterdam</cop><cop>New York, NY</cop><pub>Elsevier B.V</pub><pmid>1664272</pmid><doi>10.1016/0006-8993(91)90293-5</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0006-8993
ispartof Brain research, 1991-09, Vol.559 (1), p.109-117
issn 0006-8993
1872-6240
language eng
recordid cdi_proquest_miscellaneous_72644728
source MEDLINE; Elsevier ScienceDirect Journals
subjects Affect - physiology
Affective defense behavior
Aggression - physiology
Amygdala
Amygdala - physiology
Anatomical correlates of behavior
Animals
Behavioral psychophysiology
Biological and medical sciences
Cats
Electric Stimulation
Enkephalin, Leucine - analogs & derivatives
Enkephalin, Leucine - pharmacology
Enkephalins - physiology
Female
Fluorescent Dyes
Fundamental and applied biological sciences. Psychology
Homocysteine - analogs & derivatives
Homocysteine - pharmacology
ICI 171, 864
Immunohistochemistry
Male
Midbrain periaqueductal gray
Naloxone
Naloxone - pharmacology
Naltrexone - analogs & derivatives
Naltrexone - pharmacology
Narcotic Antagonists - pharmacology
Opioid subtype
Periaqueductal Gray - anatomy & histology
Periaqueductal Gray - physiology
Psychology. Psychoanalysis. Psychiatry
Psychology. Psychophysiology
Receptors, Opioid - physiology
Receptors, Opioid, delta
Receptors, Opioid, mu
Stereotyped Behavior - physiology
Stilbamidines
β-Funaltrexamine
title An enkephalinergic mechanism involved in amygdaloid suppression of affective defence behavior elicited from the midbrain periaqueductal gray in the cat
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T04%3A19%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20enkephalinergic%20mechanism%20involved%20in%20amygdaloid%20suppression%20of%20affective%20defence%20behavior%20elicited%20from%20the%20midbrain%20periaqueductal%20gray%20in%20the%20cat&rft.jtitle=Brain%20research&rft.au=Shaikh,%20Majid%20B.&rft.date=1991-09-13&rft.volume=559&rft.issue=1&rft.spage=109&rft.epage=117&rft.pages=109-117&rft.issn=0006-8993&rft.eissn=1872-6240&rft.coden=BRREAP&rft_id=info:doi/10.1016/0006-8993(91)90293-5&rft_dat=%3Cproquest_cross%3E72644728%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16043295&rft_id=info:pmid/1664272&rft_els_id=0006899391902935&rfr_iscdi=true